Slayback, a Princeton, N.J. based specialty pharmaceutical company, is welcoming Paul Campanelli to its board of directors.
Campanelli is the chairman of Endo Pharmaceuticals, and was, until recently, president and CEO of Endo Pharmaceuticals, where he led a turnaround focused on executing Endo's strategy to improve productivity, simplify their business, and increase the value of the company's branded, generic and international pharmaceutical assets.
"Not only is Paul a widely respected industry veteran, but I also personally have great admiration for Paul's track record in building, growing and running Par Pharmaceuticals and later the combined Endo-Par house through its numerous stages of growth and challenges," said Ajay Singh, Slayback president and CEO. "His skills, experience and personality are all a perfect fit for Slayback as we navigate our trajectory through an important and exciting phase of growth. I am absolutely delighted to have Paul join our Board and help Slayback through its next chapter."
Earlier, Campanelli served as CEO of Par Pharmaceutical Companies, following the company's September 2012 acquisition by TPG. While CEO of Par, he built the company's leadership team and a specialty pharmaceutical business with a diverse portfolio of complex generics and 505(b)2s. Under his direction, Par entered the sterile injectables segment via the JHP acquisition and its sterile injectable segment ultimately grew from a baseline of zero to over $1 billion in revenue. His success in growing Par culminated in the acquisition of Par by Endo in 2015 for over $8 billion.
Prior to Campanelli’s tenure as Par's CEO, he served as COO and president of Par Pharmaceutical, the company's generics division. Prior to joining Par, he served as vice president of business development at Dr. Reddy's.
“I am very excited to become part of the Slayback board,” Campanelli said. “Slayback, in its relatively short history, has already demonstrated an impressive ability to execute on its strategy. Ajay has built a strong team to grow the company. And the company's pipeline is robust and exciting. I am looking forward to contributing to Slayback's success."